ArticleFrontiers in endocrinology2026
Proteomics reveal serum biomarkers for early diagnosis in premature ovarian insufficiency.
Article in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Premature ovarian insufficiency (POI) leads to infertility with unclear mechanisms and scarce early diagnostic biomarkers. This study explored serum protein profiles to uncover POI molecular mechanisms and candidate biomarkers. Methods: Label-free serum proteomics was performed using serum samples from 20 POI patients, 20 healthy controls (HC) and 20 menopausal women (MP) to screen differentially expressed proteins (DEPs). Bioinformatic analyses including functional enrichment and correlation analysis were carried out. Candidate markers were evaluated by ROC analysis and validated by ELISA in an independent cohort of 88 participants. Results: Three groups had distinct proteomic profiles. We identified 54 DEPs between POI and HC, as well as 30 DEPs between POI and MP. Functional enrichment uncovered dysregulation in cytoskeleton organization and autoimmune response in POI. Five biomarkers (S100A8, S100A9, TUBA1A, TPM4, RAP1B) exhibited stable diagnostic performance across cohorts. The combined signature of S100A8 and S100A9 yielded reliable discriminatory power, and independent ELISA testing further validated their elevated serum levels and satisfactory diagnostic value for POI. Conclusions: POI is characterized by abnormal cytoskeleton homeostasis and inflammatory dysregulation. Five proteins, especially S100A8/S100A9, represent potential serum protein biomarkers for early POI diagnosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.